GU Cancers 2019 | Interaction of darolutamide with substrates of CYPs and P-gp

Christian Zurth

Highly anticipated results from the Phase I study investigating the safety of darolutamide as a comedication in non-metastatic castration-resistant prostate cancer (nmCRPC; NCT03237416), was presented at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. Here, Christian Zurth, PhD, from Bayer HealthCare, Leverkusen, Germany, reports on the results in terms of effects on CYP enzymes, demonstrating a low risk for adverse CYP-mediated drug-drug interactions.

Share this video